MP60-05 DE NOVO OVERACTIVE BLADDER AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PROSTATE CANCER

(1) Background: local treatment of the primary tumor has become a valid therapeutic option in de-novo oligo-metastatic prostate cancer (PC). However, evidence regarding radical prostatectomy (RP) in this setting is still subpar, and the effect of cytoreductive RP on postoperative health-related quality of life (HRQOL) is still unclear. (2) Methods: for the current study, patients with de-novo oligo-metastatic PC (cM1-oligo), defined as ≤5 bone lesions in the preoperative staging, were included, and matched cohorts using the variables age, body-mass index (BMI), and pT-stage were generated. Patient-reported outcome measures (PROMS) were assessed pre- and postoperatively using the validated EORTC-QLQ-C30, IIEF-5, and ICIQ-SF questionnaires. The primary endpoint for univariate and multivariable analysis was good general HRQOL defined by previously validated cut-off values. (3) Results: in total, 1268 patients (n = 84 (7%) cM1-oligo) underwent RP between 2012 and 2020 at one tertiary care center. A matched cohort of 411 patients (n = 79 with oligo-metastatic bone disease (cM1-oligo) and n = 332 patients without clinical indication of metastatic disease (cM0)) was created. The median follow-up was 25mo. There was no significant difference in good general HRQOL rates between cM1-oligo-patients and cM0-patients before RP (45.6% vs. 55.2%, p = 0.186), and at time of follow-up (44% vs. 56%, p = 0.811). Global health status (GHS) worsened significantly in cM0-patients compared to baseline (−5, p = 0.001), whereas GHS did not change significantly in cM1-oligo-patients (+3.2, p = 0.381). In multivariate analysis stratified for good erectile function (IIEF5 > 18; OR 5.722, 95% CI 1.89–17.36, p = 0.002) and continence recovery (OR 1.671, 95% CI 1.03–2.70, p = 0.036), cM1-oligo was not an independent predictive feature for general HRQOL (OR 0.821, 95% CI 0.44–1.53, p = 0.536). (4) Conclusions: in this large contemporary retrospective analysis, we observed no significant difference in HRQOL in patients with the oligometastatic bone disease after cytoreductive radical prostatectomy, when compared to patients with localized disease at time of surgery.

Download Full-text

PD18-12 DE NOVO OVERACTIVE BLADDER AFTER ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY

The Journal of Urology ◽

10.1016/j.juro.2017.02.872 ◽

2017 ◽

Vol 197 (4S) ◽

Author(s):

Yoshihisa Matsukawa ◽

Yasuhi Yoshino ◽

Yasuhito Funahashi ◽

Tsuyoshi Majima ◽

Tokunori Yamamoto ◽

...

Keyword(s):

Radical Prostatectomy ◽

Overactive Bladder ◽

De Novo ◽

Laparoscopic Radical Prostatectomy ◽

Robot Assisted

Download Full-text

De novo overactive bladder after robot-assisted laparoscopic radical prostatectomy

Neurourology and Urodynamics ◽

10.1002/nau.23556 ◽

2018 ◽

Vol 37 (6) ◽

pp. 2008-2014 ◽

Cited By ~ 6

Author(s):

Yoshihisa Matsukawa ◽

Yashushi Yoshino ◽

Shohei Ishida ◽

Takashi Fujita ◽

Tsuyoshi Majima ◽

...

Keyword(s):

Radical Prostatectomy ◽

Overactive Bladder ◽

De Novo ◽

Laparoscopic Radical Prostatectomy ◽

Robot Assisted

Download Full-text

Comparing the Survival Outcomes of Radical Prostatectomy Versus Radiotherapy for Patients With De Novo Metastasis Prostate Cancer: A Population-Based Study

Frontiers in Oncology ◽

10.3389/fonc.2021.797462 ◽

2021 ◽

Vol 11 ◽

Author(s):

Xiaoxiao Guo ◽

Haoran Xia ◽

Xiaonan Su ◽

Huiming Hou ◽

Qiuzi Zhong ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Primary Tumor ◽

Comparative Effectiveness ◽

De Novo ◽

Specific Antigen ◽

Cox Proportional Hazards ◽

Survival Outcomes ◽

Standardized Mortality Ratio ◽

The Impact

PurposeThe efficacy of local treatments (LTs) in selected patients with metastatic prostate cancer (mPCa) had been demonstrated. However, the comparative effectiveness between LTs is unclear. Here, we compared the impact of radical prostatectomy (RP) and brachytherapy (RT) on the survival outcomes of mPCa patients.Materials and MethodsmPCa patients who received RT or RP between 2004 and 2016 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Multivariable Cox proportional hazards analysis was used to evaluate the comparative risk of prostate cancer-specific mortality (CSM) and all-cause mortality (ACM) between LTs. A 1:1 propensity score matching (PSM) and adjusted standardized mortality ratio weighting (SMRW) were performed to balance the clinicopathological characteristics of the groups.ResultsOf 684 mPCa patients, 481 underwent RP and 203 received RT. After PSM, both groups included 148 cases, and RT resulted in comparable CSM versus RP [CSM: hazard ratio (HR) = 0.77, p = 0.325; ACM: HR = 0.73, p = 0.138], which was consistent with the SMRW model [CSM: HR = 0.83, p = 0.138; overall survival (OS): HR = 0.75, p = 0.132]. However, RP was associated with a lower CSM in the T1–2 subgroup (HR = 0.42, p = 0.048) and a lower ACM in the T1–2 (HR = 0.55, p = 0.031) and prostate-specific antigen (PSA) ≤20ng/ml (HR = 0.48, p = 0.022) subgroups. Besides, the results showed that the mortality risk was similar between the two groups in the T3–4, Gleason score (GS) >7, PSA >20 ng/ml, and all metastatic subgroups (all p > 0.100).ConclusionsRP could confer better survival outcomes than could RT in mPCa patients with favorable primary tumor features, but not in those with advanced primary tumor features. Moreover, the metastatic substage has limited impact on the comparative effectiveness between RP and RT. Further clinical trials are necessary to confirm the present results.

Download Full-text